

# TheraSKIN<sup>®</sup>

## Living Cell Skin Allograft

**Clinical Overview** TheraSkin is an all-human, split-thickness skin allograft with living cells and retained endogenous growth factors, and a native extracellular matrix. TheraSkin can be vascularized by the recipient following transplantation to support development of granulation tissue, which aids in epithelialization to support wound closure.<sup>1-3</sup>


**Applications** A barrier membrane for chronic wounds including:

- Diabetic Foot Ulcers
- Venous Stasis Ulcers
- Pressure Ulcers
- Dehisced Surgical Wounds

**Features & Benefits**

- **Retained Endogenous Growth Factors:** Growth factors and cytokines naturally present in the donated tissue are retained in the donor's extracellular matrix, to support healing.
- **Intact ECM:** TheraSkin ECM provides a natural skin environment to enable a number of functions, including structural support, a substrate for cell movement, and direct interactions with the recipient cells to help facilitate and support healing.
- **Living Cells:** Viable fibroblasts and keratinocytes, the living cells found within human skin, are critical to support healing of the patient's damaged or diseased skin.





## TheraSkin Living Cell Skin Allograft

Frozen Storage (-40°C to -80°C), 5 Year Shelf Life

Note: TheraSkin may be stored in a conventional freezer (max temp of -15°C) for up to 4 weeks, but is no longer eligible to be returned.

Size		Configuration	Order Code
7.6 x 15.24 cm	3.00 x 6.00 in	Meshed Sheet	104TSXLR 103TSXL
5.1 x 7.6 cm	2.00 x 3.00 in	Meshed Sheet	102TSL
4.0 x 6.5 cm	1.57 x 2.56 in	Meshed Sheet	26TS
2.5 x 5.1 cm	1.00 x 2.00 in	Meshed Sheet	101TSS
2.5 x 2.5 cm	1.00 x 1.00 in	Meshed Sheet	100TSXS
1.75 x 1.75 cm	0.69 x 0.69 in	Meshed Sheet	3TS

Instructions for use available at [LifeNetHealth.org/IFU](https://www.lifenethealth.org/IFU)

### References

1. Flood MS, Weeks B, Anaeme KO, et al. Treatment of deep full-thickness wounds containing exposed muscle, tendon, and/or bone using a bioactive human skin allograft: a large cohort case series. *Wounds*. 2020;32(6):164-73.
2. Barbul A, Gurtner GC, Gordon H, Bakewell K, Carter MJ. Matched-cohort study comparing bioactive human split-thickness skin allograft plus standard of care to standard of care alone in the treatment of diabetic ulcers: A retrospective analysis across 470 institutions. *Wound Repair Regen*. 2020;28(1):81-9. doi:10.1111/wrr.12767.
3. Gurtner GC, Garcia AD, Bakewell K, Alarcon JB. A retrospective matched-cohort study of 3994 lower extremity wounds of multiple etiologies across 644 institutions comparing a bioactive human skin allograft, TheraSkin, plus standard of care, to standard of care alone. *Int Wound J*. 2020;17(1):55-64. doi:10.1111/iwj.13231.